Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer
- PMID: 35858763
- DOI: 10.1111/iju.14988
Editorial Comment from Dr Ide to Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer
Comment on
-
Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.Int J Urol. 2022 Oct;29(10):1195-1203. doi: 10.1111/iju.14976. Epub 2022 Jul 20. Int J Urol. 2022. PMID: 35858755
References
REFERENCES
-
- Kikuchi E, Hayakawa N, Fukumoto K, Shigeta K, Matsumoto K. Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies. Int J Urol. 2020;27:108-16.
-
- Herr HW, Milan TN, Dalbagni G. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol. 2015;33(108):e101-4.
-
- Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75-94.
-
- Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, et al. Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Int J Urol. 2022; doi: 10.1111/iju.14976.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
